newsfilter
← Latest News
Business Wire·

Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

Webcast today at 8:00 am Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression